Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study

• Published in: Nutrients Vol. 12; no. 7; p. 1991
• Main Authors: Jensen, Caroline, Fjeldheim Dale, Hanna, Hausken, Trygve, Hatlebakk, Jan Gunnar, Brønstad, Ingeborg, Lied, Gülen Arslan, Hoff, Dag Arne Lihaug
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.07.2020; MDPI
• Subjects: Animals; Appetite; Blood Glucose - drug effects; Blood pressure; Body composition; Body Composition - drug effects; Cholesterol; Cod; Diabetes; Dietary Supplements; Double-Blind Method; Double-blind studies; Family physicians; Fasting - blood; Female; Fish Proteins, Dietary - administration & dosage; Gadiformes; Glucagon-Like Peptide 1 - blood; Glucose; Health care; Humans; Insulin - blood; Lipid Metabolism - drug effects; Lipids; Lipids - blood; Male; Metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - therapy; Middle Aged; Peptides; Postprandial Period; Protein Hydrolysates - administration & dosage; Proteins; Norway; metabolic syndrome; cod protein hydrolysate; glucose metabolism; obesity; lipid metabolism
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu12071991

The risk of cardiovascular diseases and type 2 diabetes mellitus are increased in subjects with metabolic syndrome (MetS), and hydrolyzed fish protein may have favorable effects on metabolic health. Here, we investigated the effect of 8 weeks supplementation with 4 g of cod protein hydrolysate (CPH) on glucose metabolism, lipid profile and body composition in individuals with MetS in a double-blind, randomized intervention study with a parallel-group design. Subjects received a daily supplement of CPH (n = 15) or placebo (n = 15). Primary outcomes were serum fasting and postprandial glucose levels. Secondary outcomes were fasting and postprandial insulin and glucagon-like peptide 1 (GLP-1), fasting lipid concentrations and body composition. No difference was observed between CPH and placebo for insulin, glucose or GLP-1 after 8 weeks intervention. Fasting triacylglycerol decreased in both the CPH group and placebo group, with no change between groups. Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly within both groups from baseline to study end, but no difference was observed between the two groups. In conclusion, supplementing with a low dose of CPH in subjects with MetS for 8 weeks had no effect on fasting or postprandial levels of insulin, glucose or GLP-1, lipid profile or body composition.